Lundbeck Onfi Gets Dermatological Warning, Bigger Marketing Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for Eisai’s Banzel, which also has an indication limited to Lennox-Gastaut syndrome, does not mention Stevens-Johnson syndrome or toxic epidermal necrolysis cited in the Onfi warning.
You may also be interested in...
Onfi Approval Shows Benefits Of Lundbeck's Ovation Acquisition
Clobazam is approved as an add-on to therapy for a particularly severe orphan seizure disorder known as Lennox-Gastaut syndrome.
FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality
FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: